No tax




Security policy (edit with Customer reassurance module)


Delivery policy (edit with Customer reassurance module)


Return policy (edit with Customer reassurance module)

Active ingredient and dosage form

Coated Tablets light orange, biconvex, oblong, with a chamfer, with a risk on one side and an engraving "E 511" on the other side, odorless; on a break: the outer ring of the shell is light orange in color, the core of the pill is white or almost white.
1 tab. contains Cetirizine dihydrochloride 10 mg;
Excipients: silica colloidal anhydrous; Magnesium stearate; lactose monohydrate; MCC
shell: hydroxypropylmethylcellulose; titanium dioxide; macrogol 400; Ariavit "Sunset" yellow;
in the blister 5, 7 or 10 pcs.; in a carton of 1 (5, 7 or 10 tablets) or 3 blisters (10 tablets).

colorless or almost colorless, sweet, no sediment or mechanical impurities, odorless.
1 ml contains cetirizine dihydrochloride 10 mg;
Excipients: glycerol; propylene glycol; sodium saccharinate; methyl parahydroxybenzoate; propyl parahydroxybenzoate; glacial acetic acid; purified water,
in vials, droppers of dark glass, 20 ml; in a cardboard box 1 bottle.

tab., pokr. shell 10 mg: 5, 7, 10 or 30 pcs. - П № 015607/01 06.05.04
drops for oral administration 10 mg / 1 ml: fl.-drop. 20 ml - P №015607/02 06.05.04

Mechanism of action

Antiallergic.Blocker histamine H1-receptor groups of piperazine derivatives. It is the main carboxylated metabolite of hydroxyzine. Cetirizine has more polar (less lipophilic) groups attached to the side chain of ethylamine, which reduces its entry into the central nervous system, increases selectivity in relation to histamine H1-receptors, and also reduces the side effects associated with anticholinergic activity.
The drug inhibits the migration of eosinophils and inhibits the factors of eosinophil chemotaxis. Significantly reduces the accumulation of eosinophils in the skin, as well as the skin resolving response to histamine, as measured by the size of the blister and hyperemia. In addition, the drug inhibits other cells of the inflammatory infiltrate (including neutrophils).
Parlazin prevents the development and facilitates the course of allergic reactions, has antipruritic and anti-exudative action.Reduces capillary permeability, prevents the development of tissue edema, relieves spasm of smooth muscles. The effect of the drug begins 20 minutes after administration, the maximum effect develops after 1 hour, the duration of action is 24 hours.

Indications and usage

- seasonal and perennial allergic rhinitis and conjunctivitis;
- pollinosis (hay fever);
- pruritic allergic dermatosis;
- urticaria (including chronic idiopathic);
- Quincke swelling.


- lactation period (breastfeeding);
- pregnancy;
- Hypersensitivity to cetirizine or other components of the drug.
The drug is not prescribed to children under the age of 1 year due to the lack of data on the safety and efficacy of the drug in this age group.
The drug in the form of pills is not prescribed to children aged 1 to 6 years.

Pregnancy and breastfeeding

AT experimental studies Cetirizine has not been shown to have a teratogenic effect. However, data from well-controlled studies in humans are lacking, and therefore the use of Parlazin during pregnancy is not recommended.
Cetirizine passes into breast milk and may cause adverse reactions in the baby. Therefore, do not use the drug Parlazin during breastfeeding.

Adults and teenagers over 12 years old appoint 10 mg (1 tab. or 20 drops) 1 time / day, preferably at night.
Children aged 6-12 years appoint 5 mg (1/2 tab. or 10 drops) 2 times / day (morning and evening) or 10 mg (1 tab. or 20 drops) 1 time / day (evening).
Children aged 2-6 years appoint 5 mg (10 drops) 1 time / day or 2.5 mg (5 drops) 2 times / day (morning and evening).
Children aged 1-2 years prescribe 2.5 mg (5 drops) 2 times / day.
Elderly patients and patients with renal insufficiency It is recommended to reduce the daily dose to 5 mg.

Adverse reactions

From the side of the central nervous system: rarely - drowsiness (depending on the dose), feeling tired, headache, migraine, dizziness, anxiety (increased motor activity).
Gastrointestinal: dry mouth, nausea.
The intensity of the above symptoms can be reduced by dividing the daily dose into 2 doses.
Allergic reactions: rarely (<= 2%) - angioedema, rash.

With the development of hypersensitivity reactions, treatment with Parlazin should be discontinued.
In patients with renal failure due to slower elimination of the drug, cetulation of cetirizine is possible. When prescribing Parlazina in this category of patients at the recommended doses for adults, side effects associated with anticholinergic effects and effects on the central nervous system can be observed. Therefore, when using the drug in patients with impaired renal function, a dose reduction is recommended.
Elderly patients have an increased risk of developing anticholinergic effects of the drug (dry mouth, urinary retention), however, as a rule, no effect on the central nervous system occurs. When using the drug in this category of patients, a dose reduction is also recommended.
It should be borne in mind that Parlazin in the form of pills contains lactose. Therefore, patients with lactose intolerance should be informed about this.
Treatment with Parlazin should be stopped 3 days before the Prik-test in order to prevent reaction distortion.
You should refrain from the use of alcoholic beverages during the period of treatment with Parlazin.
Use in pediatrics
For treatment children aged 1 to 6 years Parlazin should be used in the form of drops for oral administration.
Parlazin in the form of pills can be used in children aged 6 years and older.
Influence on ability to drive motor transport and control mechanisms
When you first receive Parlazina should pay attention to the possibility of side effects (drowsiness). Patients are advised to refrain from driving a car or controlling mechanical devices until the side effects disappear. In the future, if you need to drive a car or when you work that requires increased attention, patients should not exceed the daily dose of 10 mg.


Symptoms: often - feeling tired, sleepy. Children have anxiety and irritability, followed by drowsiness. When taking a single dose of 50 mg may be a delay in urination, constipation.
Treatment: it is necessary to induce vomiting, flush the stomach. If necessary, supportive and symptomatic treatment should be prescribed. There is no specific antidote.Hemodialysis is not effective.

Drug Interactions

The clinically significant interaction of cetirizine with glipizide, diazepam, cimetidine, Azithromycin, pseudoephedrine, Ketoconazole, Erythromycin has not been established.
With simultaneous use of cetirizine with theophylline (400 mg / day), there is a decrease in the total clearance of cetirizine by 16%. The pharmacokinetics of theophylline does not change.

Storage conditions

The drug should be stored in a dark place at a temperature not higher than 25 ° C. Shelf life - 2 years. An open bottle with drops for ingestion should be stored no more than 4 weeks.

The drug is approved for use as a means of OTC.


42 Items